

s 22(1)(a)(ii)

From: Aisha Chambers <aisha.chambers@go.womenleadersinstitute.com>
Sent: Friday, 9 February 2024 9:00 AM
To: s 22(1)(a)(ii) @pmc.gov.au
Subject: s 22(1)(a)ready to take your STEMM career to the next level?

Dear s 22(1)(a)

Are you looking to accelerate your STEMM career but struggling to overcome engrained biases?

Uncover tangible strategies to ignite your potential at the **Women in STEMM Leadership Summit (Naarm/Melbourne, March 13-14)** with interactive scenario-based breakout sessions on:

- Building a Personal Brand
- Transitioning from Technical Roles to Management
- Combatting Imposter Syndrome and Celebrating Yourself
- *And more!*

[Access the summit program here.](#)

The summit will host a distinguished line-up of speakers including:

s 22(1)(a)(ii)

- **Jackie Fairley**, Chief Executive Officer, **Starpharma**; Non-Executive Director, **Mirrabooka Investments**

Here's what past attendees have said:

- *'I found the event, speakers and workshops informative and very engaging. I have walked away from this event with some very valuable insights.'* – **PACCAR Australia**
- *'Speakers were inspirational and the event was extremely well-organised, practical and useful.'* – **New South Wales Education Standards Authority**

To learn more about the speaker line-up and event details, please [access the brochure here](#). Event information is also available online at stemm.womenleadersummit.com.

Looking forward to seeing you in March!

If this summit is not of interest then please opt-out of the event updates [here](#).

Regards,
 Aisha Chambers
 Campaign Manager

E aisha.chambers@womenleadersinstitute.com



P +61 2 8378 4334

Women Leaders Institute

Level 12

2 Bulletin Place,

Sydney 2000 NSW

womenleadersinstitute.org/upcoming-events

Unsubscribe from the event [emails here.](#)

s 22(1)(a)(ii)

From: Aisha Chambers <aisha.chambers@go.womenleadersinstitute.com>
Sent: Thursday, 23 November 2023 2:49 PM
To: s 22(1)(a)(ii)
Subject: Announcing the 2nd Annual Women in STEMM Leadership Summit 2024

Dear s 22(1)(a)

Following the resounding success of 2023, we are excited to announce the return of the **Women in STEMM Leadership Summit** in **Naarm / Melbourne** from **13-14 March 2024**.

10% of event proceeds will be donated to our official event charity partner, the **National Breast Cancer Foundation**, to raise funds for life-changing breast cancer research in the areas of prevention and risk, detection, and new and improved treatments.

[Access the summit program here.](#)

Join us to discover actionable insights from inspiring and diverse leaders across STEMM industries who are **empowering change to break the bias**, including:

s 22(1)(a)(ii)

- **Jackie Fairley**, Chief Executive Officer, **Starpharma**

s 22(1)(a)(ii)

To learn more about the speaker line-up and event details, please [access the brochure here](#). Event information is also available online at stemm.womenleadersummit.com.

Looking forward to welcoming you early next year!

If this summit is not of interest then please opt-out of the event updates [here](#).

Regards,
Aisha Chambers
Campaign Manager
E aisha.chambers@womenleadersinstitute.com



P +61 2 8378 4334
Women Leaders Institute

Level 12

2 Bulletin Place,

Sydney 2000 NSW

womenleadersinstitute.org/upcoming-events


P.S. Passionate about STEMM and interested in attending the Summit but don't have access to funding? Apply for our Women Leaders Institute Scholarship [here](#).

Unsubscribe from the event [emails here](#).

COVID-19 Vaccines and Treatments: State of Play – w/e 6 August 2021


Additions since last circulation (25 July 2021) in red text. Previous data is available from earlier reports if required.

s 22(1)(a)(ii)



Contents

s 22(1)(a)(ii)



Treatments	38
------------------	----

- **VIRALEZE /SPL7013 – Starpharma** (anti-viral) registered as a device
 - On 3 March 2021, Starpharma announced SPL7013 is active against other pandemic coronaviruses (SARS and MERS).
 - Pre-clinical data show the anti-viral nasal spray is virucidal and inactivates more than 99.0% of SARS-CoV-2, as well as minimal cellular toxicity.
 - No clinical data as of yet, however a double-blind, placebo-controlled, safety, tolerability and PK study of VIRALEZE nasal spray currently underway
 - SPL7013 is a large dendrimer made up of two approved products (VivaGel for bacterial vaginosis and VivaGel antiviral condom). Both products have been shown to be safe and well tolerated in clinical trials.
 - Europe product launch is planned for Q1 2021. Currently being manufactured for rapid roll-out following approval.



PROTECTED

COVID-19 Update – 26 March 2021

s 22(1)(a)(ii)

PROTECTED

s 22(1)(a)(ii)

Latest Business Actions

Domestic business actions

- The SMH reports “Australian biotech **Starpharma** is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown. The Melbourne-based company announced a deal on Thursday morning [25 March] that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds’ 1400-strong pharmacy network...The company was also planning to register Viraleze in Australia, but would focus on COVID-ravaged Europe in the first instance.” (SMH) <https://www.smh.com.au/business/small-business/aussie-biotech-starpharma-signs-deal-to-sell-covid-nose-spray-in-britain-20210325-p57dvg.html>

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: Dana Lightbody <info@theleadershipinstitute.com.au>
Sent: Wednesday, 12 August 2020 11:36 AM
To: s 22(1)(a)(ii)
Subject: Leadership opportunities in a (post) COVID Environment



Hi there,

The last couple of months have had a big impact on the business environment, but do you know how to take advantage of the opportunities that are being presented to you during this time?

The [Women in Leadership Summit](#) brings together exceptional women to help you grow both personally and professionally so that you can strive for excellence with purpose, motivation and authenticity.

We know that attending events physically may not be in our near future, which is why we now offer the option to livestream!

Join us to hear from the following keynote speakers:

s 22(1)(a)(ii)

- **Staying true to your values: The role of authenticity, integrity and community in leadership** | Facilitated by **Jackie Fairley** - CEO of **Starpharma**

View the full agenda and speaker line-up by visiting our website and downloading the agenda today!

[Learn more>](#)

[Register now>](#)

I look forward to seeing you join us even if it's from the comfort of your home,

Dana Lightbody
CEO
The Leadership Institute

Konnect Learning, Level 2, 49-51 York Street, Sydney, NSW, 02 8248 0200

[Unsubscribe](#) [Manage preferences](#)

s 22(1)(a)(ii)

From: s 22(1)(a)(ii) @health.gov.au <[redacted]@health.gov.au>
Sent: Wednesday, 16 September 2020 9:45 AM
To: Hill, Sally; Thompson, Malcolm
Cc: s 47F [redacted]
Subject: Information from s 47F [redacted] - Department of Health [SEC=OFFICIAL]

Good Morning,
Apologies for the delay in providing these. Please see below information from s 47F [redacted]
Kind Regards
s 22(1)(a)(ii) Executive Assistant to
s 47F [redacted] Assistant Secretary

COVID-19 Vaccine Strategy Taskforce
Health Economics & Research Division
Department of Health
T: s 22(1)(a)(ii) [redacted] E: s 22(1)(a)(ii) [redacted] @health.gov.au


Location: Sirius Building 10.S.112


GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

s 22(1)(a)(ii)

s 22(1)(a)(ii)



- Cross-cutting
s 22(1)(a)(ii)
- 

s 22(1)(a)(ii)

- an intranasal spray, utilising an already-marketed, broad-spectrum antiviral dendrimer for COVID-19 (Starpharma Pty Ltd)

s 22(1)(a)(ii)

s 22(1)(a)(ii)

From: The Leadership Institute <info@theleadershipinstitute.com.au>
Sent: Tuesday, 21 July 2020 10:07 AM
To: s 22(1)(a)(ii)
Subject: Women in Leadership Summit tickets



Hi there,

As much as you want to achieve excellence in your field of work, it's important to understand that personal growth and improvement contributes directly to your professional development. The purpose of the [Women in Leadership Summit](#) is to help you grow both personally and professionally so that you can strive for excellence with purpose, motivation and authenticity.

Learn to hone your leadership skills - to empower others, to show resilience and for women to support and promote each other by joining the below female leaders in their keynote and panel discussion sessions:

s 22(1)(a)(ii)

- **Staying true to your values: The role of authenticity, integrity and community in leadership** | Facilitated by **Jackie Fairley** - *CEO of Starpharma*

View the full agenda and speaker line-up by visiting our website and downloading the agenda today!

[Learn more>](#)

[Register now>](#)

I look forward to seeing you join us,

Dana Lightbody

CEO

The Leadership Institute

Konnect Learning, Level 2, 49-51 York Street, Sydney, NSW, 02 8248 0200

[Unsubscribe](#) [Manage preferences](#)

s 22(1)(a)(ii)

From: Laffan, David
Sent: Friday, 29 May 2020 4:39 PM
To: Jackie Fairley
Subject: Accepted: Starpharma - COVID Nasal Spray Discussion [SEC=OFFICIAL]

OFFICIAL

From: [Jackie Fairley](#)
To: [Tony Eglezos](#); [Jeremy Paull](#); [Laffan, David](#)
Subject: Starpharma - COVID Nasal Spray Discussion

David Laffan


Assistant Secretary (Health)

p **s 22(1)(a)(ii)**, **s 22(1)(a)(ii)**

e david.laffan@pmc.gov.au <mailto:david.laffan@pmc.gov.au>

National COVID-19 Coordination Commission Department of the Prime Minister and Cabinet pmc.gov.au/nccc

s 22(1)(a)(ii)



WOMEN IN LEADERSHIP

Supported by: UN Women Australia

Endorsing Partner: Diversity Council Australia

Naarm | Melbourne

29-30 November 2022 (Tuesday & Wednesday)

BREAKING BARRIERS, BUILDING LEGACIES

Invited

Jackie Fairley, Chief Executive Officer, Starpharma

s 22(1)(a)(ii)

